※ 본 기사문(영문ver.)은 (주)도프의 이슈를 다룬 기사를 자체적으로 영문번역하였음을 밝힙니다.

 

 

기사 원문 : 도프, 무세포 동종 진피 조직이식 1500건...부작용 ‘제로’ (edaily.co.kr)

 

 

DOF, a biomaterial-based medical device company, has proven the safety of the ‘supercritical fluid technology’ developed for the first time in the world in the market. By demonstrating differentiated competitiveness, DOF plans to use this to accelerate its entry into advanced global medical device markets such as the United States and China.

 

DOF announced on the 4th that the acellular allogeneic dermal tissue transplant material ‘ADM’ (product name: SC DERM) has not had a single report of infection or ineligible result in over 1,500 transplants since its launch last year.

 

Shin Yong-woo, CEO of DOF. (Photo = DOF)

 

World's first successful evaluation of commercialization of supercritical fluid technology

 

ADM using supercritical fluid technology is a transplant material made by decellularizing donated human skin. Decellularization is a process that removes the cause of immune rejection and is a must-go process when transplanting allogeneic dermis to a patient.

 

Supercritical fluid technology turns carbon dioxide, which is not harmful to the human body, into a supercritical state and renders cells acellular. It is based on a method of raising the pressure of carbon dioxide above a certain level and adjusting the temperature appropriately to make it into an intermediate state between liquid and gas.

DOF took advantage of this and obtained tissue banking permission from the Ministry of Food and Drug Safety in 2021. Since last year, we have been producing acellular allogeneic dermis and allogeneic nerve using supercritical fluid technology and supplying them to major general hospitals in Korea. In particular, Exogen of the United States is virtually the only company that has succeeded in commercializing allogeneic nerves.

 

Lee Gyu-ho, head of DOF Sales Division, said, “Through the paper, we confirmed that DOF’s ADM is superior in extracellular matrix, collagen, and elastin residual content compared to competitors,” and added, “We presented this at the recently held ‘2023 Korean Society of Canine and Joint Medicine’, establishing a new market for allogeneic dermal dermis. “It announced the times,” he emphasized.

 

He added, “DOF’s ADM is most often used not only for rotator cuff surgery, but also for skin reconstruction in patients with bedsores and burns, and breast reconstruction after breast cancer surgery,” adding, “Patient satisfaction is high as the growth factors of living tissue are maintained the most.” .

 

Differentiated competitiveness driving DOF’s growth...preparing to enter the U.S. and China

 

Differentiated competitiveness is driving DOF’s rapid growth. Last year, when the company began selling products, sales amounted to just 1.5 billion won, mainly centered around plastic human implants. However, as word of mouth spreads and revenue sources diversify into orthopedics, urology, and nerves, a significant increase is expected this year. DOF aims to achieve sales of 10 billion won for the first time this year. It is also expected to cruise to 28 billion won next year and 50 billion won in 2025.

 

Director Lee said, “Human tissue transplant materials using supercritical fluid technology have secured not only safety but also eco-friendliness and price competitiveness,” adding, “Based on this, we will change the market paradigm.”

 

The market is also big. According to the industry, the market for breast reconstruction acellular allogeneic dermis for breast cancer patients alone is estimated to be worth 100 billion won domestically and 6 trillion won globally this year. This is the background for which DOF is confident of rapid growth.

 

We are also speeding up preliminary work to enter the key overseas markets of the United States and China. Last month, DOF completed the patent registration of ‘collagen separation method based on supercritical fluid technology’ in the United States. This is a technology that can extract collagen from discarded liposuction effluent with high purity. In the same month, a patent was registered in China for ‘animal fat-derived extracellular matrix and animal fat-derived extracellular matrix preservation solution.’ This is a technology that can effectively extract extracellular matrix from animal fat based on supercritical fluid technology.

 

Director Lee said, “We have proven our technological prowess and competitiveness through successive patent registrations in the U.S. and China,” adding, “We will settle in the domestic market this year and begin exporting in earnest next year.”

 

Meanwhile, in recognition of its growth potential, DOF attracted a total of 15.6 billion won in investment this year from venture investment companies such as HB Investment, Now Ivy, TS Investment, and DTN Investment. We are planning to list on KOSDAQ through technology special provisions in 2025. The underwriter is Korea Investment & Securities.